Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo.

about

Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo.

Item

http://www.wikidata.org/entity/Q42266741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@en

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@nl

type

Item

label

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@en

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@nl

prefLabel

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@en

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@nl

P1476

Biliverdin Reductase inhibitor ...... ed hyperbilirubinemia in vivo.

@en

P2093

Dirk R de Waart

http://www.w3.org/2001/XMLSchema#string

Piter J Bosma

http://www.w3.org/2001/XMLSchema#string

Remco van Dijk

http://www.w3.org/2001/XMLSchema#string

Ronald Oude Elferink

http://www.w3.org/2001/XMLSchema#string

Suzanne Duijst

http://www.w3.org/2001/XMLSchema#string

Ulrich Beuers

http://www.w3.org/2001/XMLSchema#string

P2860

Heme oxygenase and heme degradation

Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates

Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man

Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals

Antileukotrienes in upper airway inflammatory diseases

Bilirubin is an antioxidant of possible physiological importance

Reverse-phase h.p.l.c. separation, quantification and preparation of bilirubin and its conjugates from native bile. Quantitative analysis of the intact tetrapyrroles based on h.p.l.c. of their ethyl anthranilate azo derivatives

Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene

Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats.

Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.

P2888

s41598-017-01602-w

P304

1646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-01602-W

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stan F van de Graaf

Jurgen Seppen

Sem J Aronson

P577

2017-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085330983

http://www.w3.org/2001/XMLSchema#string

P698

28490767

http://www.w3.org/2001/XMLSchema#string

P921

bilirubin metabolic disorder

P932

5431759

http://www.w3.org/2001/XMLSchema#string